Paradoxically, while NOX2 inhibition exacerbates inflammation by disrupting redox-metabolic homeostasis, targeted activation restores metabolic balance and alleviates pathology, indicating strategic ROS modulation—not suppression—as a promising therapeutic paradigm for psoriasis. This evidence concerns the gene CYBB and psoriasis.